Daejeon
South Korea
11
2022-07-07
10
2025-11-18
These are the the leading inventors for applications assigned to PharmAbcine Inc.:
PharmAbcine Inc. based in Daejeon, KR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
ANTI-TIE2 ANTIBODY AND USE THEREOF
#2 | 2021-02-25 ✅ Patent 11,407,834 granted on 2022-08-09Anti-PD-L1 antibody and use thereof
#3 | 2021-01-14ANTI-VEGFR-2 ANTIBODY
#4 | 2020-12-31 ✅ Patent 11,407,833 granted on 2022-08-09Anti-VISTA antibody and use thereof
#5 | 2018-07-26 ✅ Patent 10,155,817 granted on 2018-12-18Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same
#6 | 2017-11-16 ✅ Patent 10,597,457 granted on 2020-03-24EGFRvIII antibody and composition comprising same
#7 | 2017-08-17 ✅ Patent 10,106,622 granted on 2018-10-23Human antibody specific to c-Met and preparation method thereof
#8 | 2015-11-05 ✅ Patent 9,963,512 granted on 2018-05-08Dual-target antibody targeting VEGFR-2 and DLL4, and pharmaceutical composition including same
#9 | 2014-09-25 ✅ Patent 9,249,220 granted on 2016-02-02Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#10 | 2014-09-18 ✅ Patent 9,249,219 granted on 2016-02-02Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
#11 | 2011-03-17 ✅ Patent 9,150,650 granted on 2015-10-06Human monoclonal antibody neutralizing vascular endothelial growth factor receptor and use thereof
Also check out PHARMABCINE INC.'s (Daejeon, South Korea) applicant profile with 11 patent applications submitted.
101351 ⎘